CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 94 of 94 entries

View as:

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02681861 Org: User:

Start: 01/31/16 End: 12/31/16 Due: 12/31/17

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Phase: N/A Priority: Normal

NCT ID: NCT01565694 Org: User:

Start: 08/14/12 End: 04/28/16 Due: 04/28/17

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa

Phase: N/A Priority: Normal

NCT ID: NCT02021318 Org: User:

Start: 03/12/14 End: 11/06/19 Due: 11/06/20

A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

Phase: N/A Priority: Normal

NCT ID: NCT02225093 Org: User:

Start: 10/02/13 End: 02/03/14 Due: 02/03/15

A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

Phase: N/A Priority: Normal

NCT ID: NCT01611363 Org: User:

Start: 10/27/11 End: 02/03/12 Due: 02/03/13

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01657981 Org: User:

Start: 02/28/07 End: 03/31/07 Due: 03/31/08

A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02034734 Org: User:

Start: 09/30/12 End: 12/31/12 Due: 12/31/13

A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans

Phase: N/A Priority: Normal

NCT ID: NCT01981928 Org: User:

Start: 11/30/13 End: 05/31/14 Due: 05/31/15

A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178

Phase: N/A Priority: Normal

NCT ID: NCT01663961 Org: User:

Start: 09/30/08 End: 12/31/08 Due: 12/31/09

Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes

Phase: N/A Priority: Normal

NCT ID: NCT00994292 Org: User:

Start: 09/30/09 End: 03/31/11 Due: 03/31/12

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)

Phase: N/A Priority: Normal

NCT ID: NCT01613586 Org: User:

Start: 05/31/12 End: 03/18/14 Due: 03/18/15

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

Phase: N/A Priority: Normal

NCT ID: NCT01655056 Org: User:

Start: 06/30/06 End: 11/30/06 Due: 11/30/07

Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)

Phase: N/A Priority: Normal

NCT ID: NCT01799902 Org: User:

Start: 12/31/11 End: 10/31/13 Due: 10/31/14

A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men

Phase: N/A Priority: Normal

NCT ID: NCT02138799 Org: User:

Start: 07/31/13 End: 09/30/13 Due: 09/30/14

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Phase: N/A Priority: Normal

NCT ID: NCT01646294 Org: User:

Start: 01/31/05 End: 05/31/05 Due: 05/31/06

Drug to Drug Interaction Study With Ipragliflozin and Furosemide

Phase: N/A Priority: Normal

NCT ID: NCT01611415 Org: User:

Start: 07/31/11 End: 10/31/11 Due: 10/31/12

A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652

Phase: N/A Priority: Normal

NCT ID: NCT02243657 Org: User:

Start: 05/31/09 End: 05/31/10 Due: 05/31/11

Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal

NCT ID: NCT00673725 Org: User:

Start: 03/31/08 End: 09/30/08 Due: 09/30/09

A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02108548 Org: User:

Start: 04/30/14 End: 03/31/15 Due: 03/31/16

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects	NCT02681861	Astellas Pharma Europe B.V.	user2@example.com	None	2016-01-31	2016-12-31	2017-12-31	-	-	2025-07-14
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity	NCT01565694	Astellas Pharma Europe B.V.	user2@example.com	None	2012-08-14	2016-04-28	2017-04-28	-	-	2025-07-14
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa	NCT02021318	Astellas Pharma Europe B.V.	user2@example.com	None	2014-03-12	2019-11-06	2020-11-06	-	-	2025-07-14
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer	NCT02225093	Astellas Pharma Europe B.V.	user2@example.com	None	2013-10-02	2014-02-03	2015-02-03	-	-	2025-07-14
A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin	NCT01611363	Astellas Pharma Europe B.V.	user2@example.com	None	2011-10-27	2012-02-03	2013-02-03	-	-	2025-07-14
A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects	NCT01657981	Astellas Pharma Europe B.V.	user2@example.com	None	2007-02-28	2007-03-31	2008-03-31	-	-	2025-07-14
A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects	NCT02034734	Astellas Pharma Europe B.V.	user2@example.com	None	2012-09-30	2012-12-31	2013-12-31	-	-	2025-07-14
A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans	NCT01981928	Astellas Pharma Europe B.V.	user2@example.com	None	2013-11-30	2014-05-31	2015-05-31	-	-	2025-07-14
A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178	NCT01663961	Astellas Pharma Europe B.V.	user2@example.com	None	2008-09-30	2008-12-31	2009-12-31	-	-	2025-07-14
Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes	NCT00994292	Astellas Pharma Europe B.V.	user2@example.com	None	2009-09-30	2011-03-31	2012-03-31	-	-	2025-07-14
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)	NCT01613586	Astellas Pharma Europe B.V.	user2@example.com	None	2012-05-31	2014-03-18	2015-03-18	-	-	2025-07-14
A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body	NCT01655056	Astellas Pharma Europe B.V.	user2@example.com	None	2006-06-30	2006-11-30	2007-11-30	-	-	2025-07-14
Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)	NCT01799902	Astellas Pharma Europe B.V.	user2@example.com	None	2011-12-31	2013-10-31	2014-10-31	-	-	2025-07-14
A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men	NCT02138799	Astellas Pharma Europe B.V.	user2@example.com	None	2013-07-31	2013-09-30	2014-09-30	-	-	2025-07-14
A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions	NCT01646294	Astellas Pharma Europe B.V.	user2@example.com	None	2005-01-31	2005-05-31	2006-05-31	-	-	2025-07-14
Drug to Drug Interaction Study With Ipragliflozin and Furosemide	NCT01611415	Astellas Pharma Europe B.V.	user2@example.com	None	2011-07-31	2011-10-31	2012-10-31	-	-	2025-07-14
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652	NCT02243657	Astellas Pharma Europe B.V.	user2@example.com	None	2009-05-31	2010-05-31	2011-05-31	-	-	2025-07-14
Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis	NCT00673725	Astellas Pharma Europe B.V.	user2@example.com	None	2008-03-31	2008-09-30	2009-09-30	-	-	2025-07-14
A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects	NCT02108548	Astellas Pharma Europe B.V.	user2@example.com	None	2014-04-30	2015-03-31	2016-03-31	-	-	2025-07-14